Braxia Scientific Corp.
BRAXF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $1 |
| % Growth | -17.1% | -1% | 14.9% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $2 |
| Gross Profit | $0 | $0 | -$0 | -$1 |
| % Margin | 16.6% | 0.8% | -22.2% | -192.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $0 | $0 | $2 |
| SG&A Expenses | $1 | $0 | $0 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $0 | $1 | $1 |
| Operating Income | -$1 | -$0 | -$1 | -$2 |
| % Margin | -198.4% | -43.7% | -131.5% | -438.1% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$6 |
| Pre-Tax Income | -$1 | -$0 | -$1 | -$8 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$1 | -$0 | -$1 | -$8 |
| % Margin | -184.2% | -45.9% | -133.7% | -1,465.8% |
| EPS | -0.003 | -0.001 | -0.003 | -0.029 |
| % Growth | -240% | 66.7% | 89.7% | – |
| EPS Diluted | -0.003 | -0.001 | -0.003 | -0.029 |
| Weighted Avg Shares Out | 264 | 264 | 264 | 264 |
| Weighted Avg Shares Out Dil | 264 | 264 | 264 | 264 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$0 | -$1 | -$2 |
| % Margin | -164% | -29.2% | -123.6% | -407.1% |